HC Wainwright Issues Positive Estimate for KROS Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – HC Wainwright raised their Q1 2025 earnings estimates for shares of Keros Therapeutics in a report issued on Thursday, February 27th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($1.27) per share for the quarter, up from their prior estimate of ($1.51). HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q2 2025 earnings at ($1.39) EPS, Q3 2025 earnings at ($1.30) EPS, Q4 2025 earnings at ($1.41) EPS, FY2025 earnings at ($5.36) EPS, FY2026 earnings at ($6.02) EPS, FY2027 earnings at ($6.63) EPS, FY2028 earnings at ($4.37) EPS and FY2029 earnings at ($2.50) EPS.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million.

A number of other brokerages have also recently weighed in on KROS. Cantor Fitzgerald cut Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Scotiabank decreased their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research note on Thursday, January 16th. BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Piper Sandler decreased their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, January 17th. Finally, Wedbush downgraded Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $47.00 to $15.00 in a research note on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Stock Performance

KROS opened at $11.59 on Monday. Keros Therapeutics has a one year low of $9.77 and a one year high of $72.37. The stock has a market capitalization of $469.48 million, a P/E ratio of -2.22 and a beta of 1.39. The business’s 50-day simple moving average is $12.30 and its 200-day simple moving average is $39.01.

Institutional Trading of Keros Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KROS. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Emerald Mutual Fund Advisers Trust purchased a new position in shares of Keros Therapeutics during the third quarter valued at approximately $6,539,000. Emerald Advisers LLC acquired a new stake in Keros Therapeutics during the third quarter worth approximately $9,032,000. AlphaCentric Advisors LLC purchased a new position in shares of Keros Therapeutics during the 3rd quarter worth $465,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of Keros Therapeutics during the third quarter worth $216,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.